• We offer tailored partnerships to support and transform drug discovery.

    Every collaboration is a bespoke arrangement, meticulously designed to discover new compounds and targets in patient relevant disease models.

  • MIMETAS offers flexible fee-for-service solutions for therapy prioritization, optimization, and de-risking of compounds.

    As an extension of your team, MIMETAS provides the expertise and resources needed for effective research and development.

  • Our OrganoReady program is made for you when you need optimized assays for investigational toxicology.

    We guarantee OrganoReady performance according to specifications, in a fast and convenient sales transaction with a clear fee structure.

  • Giving you some food for thought. Read our blogs to learn more about 3D tissue culture, research backgrounds, developments, and its future outlook.
  • Get inspired by research done by our scientists, partners, and customers around the globe.

  • Learn about our mission, vision, the history of the company, and find out what we mean with MIMETAS-do.
open menu icon close menu icon
EN

Poster: NephroScreen: Nephrotoxicity and Drug Interaction Study Using a Human Proximal Tubule-On-A-Chip

Drug-induced kidney injury (DIKI) poses a risk to renal proximal tubules, potentially resulting in kidney failure and acting as a limiting factor in pharmacotherapy. DIKI is responsible for causing 14-26% of acute kidney injury cases, highlighting its significance in clinical settings. This stark contrast emphasizes the urgent requirement for improved predictive models to assess nephrotoxicity during the discovery and early development of drugs.

In this poster, we present a high throughput, standardized and automatable OrganoPlate® platform for the detection of drug-induced nephrotoxicity. The OrganoPlate® 3-lane was combined with renal proximal tubule epithelial cell lines (PTEC) and exposed to fluid shear stress. Additionally, this model was exposed to known and blinded nephrotoxic compounds to explore nephrotoxicity and drug-transporter interactions. we present a 3D microfluidic primary human brain microvascular endothelial cell (HBMEC) BBB model with relevant junction and transporter expression, tight and selectively permeable barriers, response to known toxicants, and suitability for high-throughput, on-chip TEER measurements.

 

 

 

 

Download the poster here

Cookies

May we use cookies?
Hi there! Thanks for visiting our website. We use cookies to keep track of our website statistics to optimize the user experience. We also use cookies for marketing purposes. You can set your preferences by selecting the options below. Terms of Use & Privacy Policy
Accept all
Accept selected
Decline all